DE60204767D1 - Metallsubstituierte, nicht zentrosymmetrische phthalocyanin-analoga, deren herstellung und verwendung zur photodynamischen therapie, und als in-vivo-diagnostikum - Google Patents

Metallsubstituierte, nicht zentrosymmetrische phthalocyanin-analoga, deren herstellung und verwendung zur photodynamischen therapie, und als in-vivo-diagnostikum

Info

Publication number
DE60204767D1
DE60204767D1 DE60204767T DE60204767T DE60204767D1 DE 60204767 D1 DE60204767 D1 DE 60204767D1 DE 60204767 T DE60204767 T DE 60204767T DE 60204767 T DE60204767 T DE 60204767T DE 60204767 D1 DE60204767 D1 DE 60204767D1
Authority
DE
Germany
Prior art keywords
phthalocyanine
analogues
useful
photodynamic therapy
carriers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60204767T
Other languages
English (en)
Other versions
DE60204767T2 (de
Inventor
Gabrio Roncucci
Donata Dei
Filippis Maria De
Lia Fantetti
Daniele Nistri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molteni and C SpA
Original Assignee
Molteni and C SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molteni and C SpA filed Critical Molteni and C SpA
Application granted granted Critical
Publication of DE60204767D1 publication Critical patent/DE60204767D1/de
Publication of DE60204767T2 publication Critical patent/DE60204767T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60204767T 2001-03-21 2002-03-20 Metallsubstituierte, nicht zentrosymmetrische phthalocyanin-analoga, deren herstellung und verwendung zur photodynamischen therapie, und als in-vivo-diagnostikum Expired - Lifetime DE60204767T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01106411 2001-03-21
EP01106411 2001-03-21
PCT/EP2002/003108 WO2002090361A1 (en) 2001-03-21 2002-03-20 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic

Publications (2)

Publication Number Publication Date
DE60204767D1 true DE60204767D1 (de) 2005-07-28
DE60204767T2 DE60204767T2 (de) 2006-05-18

Family

ID=8176785

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60204767T Expired - Lifetime DE60204767T2 (de) 2001-03-21 2002-03-20 Metallsubstituierte, nicht zentrosymmetrische phthalocyanin-analoga, deren herstellung und verwendung zur photodynamischen therapie, und als in-vivo-diagnostikum

Country Status (14)

Country Link
US (1) US7153841B2 (de)
EP (1) EP1381611B1 (de)
JP (1) JP2004529171A (de)
CN (1) CN100351255C (de)
AT (1) ATE298341T1 (de)
AU (1) AU2002341034B2 (de)
CA (1) CA2441386C (de)
DE (1) DE60204767T2 (de)
DK (1) DK1381611T3 (de)
ES (1) ES2244793T3 (de)
IL (2) IL158032A0 (de)
PT (1) PT1381611E (de)
WO (1) WO2002090361A1 (de)
ZA (1) ZA200308093B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60223904T2 (de) 2001-01-26 2008-11-27 Btg International Ltd. Benzylaminanalogen
ATE299705T1 (de) 2002-04-25 2005-08-15 Molteni & C Metallphthalocyanin-analoge enthaltende antibakterielle zusammensetzungen
ITFI20020200A1 (it) 2002-10-21 2004-04-22 Molteni & C Dei Flii Alitti S P A Societa L Porfirine meso-sostituite.
ITFI20050092A1 (it) 2005-05-05 2006-11-06 Molteni & C Derivati ftalocianinici, processo per la loro preparazione, composizioni farmaceutiche che li contengono e loro uso
ITFI20050093A1 (it) * 2005-05-05 2006-11-06 Molteni & C Processo per la preparazione di cloruri di derivati ftalocianinici comprendenti almeno un gruppo ammonio quaternario
WO2007000472A1 (en) * 2005-06-29 2007-01-04 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Self-sterilizing products
US8524891B2 (en) * 2005-07-14 2013-09-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Tetraazaporphyrin-based compounds and their uses
CN1939919B (zh) * 2005-09-30 2010-06-09 中国科学院福建物质结构研究所 一种广谱、低毒性的酞菁类杀菌剂及其制备方法和用途
GB0520436D0 (en) * 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
EP2072584B1 (de) 2007-12-17 2011-05-11 ILFORD Imaging Switzerland GmbH Phthalocyanin-Farbstoffe, ihre Herstellung und Verwendung
WO2011089509A1 (en) * 2010-01-22 2011-07-28 Council Of Scientific & Industrial Research A process for the preparation of novel porphyrin derivatives and their use as pdt agents and fluorescence probes
WO2012086857A1 (ko) * 2010-12-21 2012-06-28 (주)파낙스이엠 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
ITFI20110166A1 (it) * 2011-08-05 2013-02-06 Molteni & C Nuovi fotosensibilizzanti ad uso terapeutico.
CN103382205B (zh) * 2012-05-03 2015-10-28 中国医学科学院生物医学工程研究所 骨靶向的酞菁锌及制备方法及用途
KR101933620B1 (ko) * 2012-09-18 2018-12-28 삼성전자주식회사 소포를 검출하기 위한 조성물, 키트 및 이를 이용하여 소포를 분석하는 방법
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
JP6269946B2 (ja) * 2014-03-25 2018-01-31 国立大学法人名古屋大学 細菌の増殖抑制
CN104262350B (zh) * 2014-10-09 2017-01-18 福州大学 一种酞菁金属配合物及其制备方法和应用
CN105418643B (zh) * 2015-12-22 2017-10-20 福州大学 一种双边生物素‑酞菁锌轭合物及其制备和应用
CN106866721B (zh) * 2017-03-10 2019-03-26 江苏省原子医学研究所 一种硅酞菁衍生物及其制备生物素受体靶向硅酞菁光敏剂的应用
CN108498855B (zh) * 2018-05-09 2021-04-27 福州大学 一种抗菌止血溶胶及其制备方法
WO2021261546A1 (ja) * 2020-06-24 2021-12-30 国立大学法人 東京大学 光増感色素
CN112409365B (zh) * 2020-12-09 2021-11-02 福州大学 3-磺酸基丙烷巯基修饰酞菁及其制备方法与在制药领域的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0434727A4 (en) * 1988-09-08 1994-08-17 Ultra Diagnostic Corp Red-shifted phthalocyanine and tetrabenztriazaporphyrin reagents
JPH0672873A (ja) * 1992-08-27 1994-03-15 Nippon Shokubai Co Ltd 腫瘍治療剤および腫瘍光化学診断薬
GB9405970D0 (en) * 1994-03-25 1994-05-11 Secr Defence Substituted phthalocyanines
CN1053906C (zh) * 1996-10-15 2000-06-28 福州大学 酞菁锌配合物及其制造方法和在制抗癌药中的应用
DE19731741A1 (de) * 1997-07-23 1999-01-28 Deutsches Krebsforsch Konjugat zur Unterscheidung von krankhaftem und gesundem Gewebe
IT1294325B1 (it) * 1997-08-14 1999-03-24 Molteni L E C Dei Fratelli Ali Zinco-ftalocianine e relativi coniugati, preparazione e uso nella terapia fotodinamica e come diagnostici
CZ20021974A3 (cs) * 1999-12-08 2002-11-13 Gentian As Substituované ftalocyaniny, způsob jejich výroby a farmaceutický prostředek obsahující tyto sloučeniny
JP4139539B2 (ja) * 2000-01-21 2008-08-27 富士フイルム株式会社 光重合性画像記録材料及び平版印刷版原版
EP1164135B1 (de) * 2000-06-15 2004-02-18 L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI Substituierte Metallphthalocyaninen, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
PT1381611E (pt) 2005-11-30
CN1633437A (zh) 2005-06-29
WO2002090361A8 (en) 2004-05-21
ZA200308093B (en) 2004-07-08
CA2441386C (en) 2010-12-21
IL158032A0 (en) 2004-03-28
EP1381611A1 (de) 2004-01-21
DE60204767T2 (de) 2006-05-18
IL158032A (en) 2009-09-01
AU2002341034B2 (en) 2007-06-14
DK1381611T3 (da) 2005-10-24
CN100351255C (zh) 2007-11-28
JP2004529171A (ja) 2004-09-24
ES2244793T3 (es) 2005-12-16
EP1381611B1 (de) 2005-06-22
US20040156787A1 (en) 2004-08-12
WO2002090361A1 (en) 2002-11-14
US7153841B2 (en) 2006-12-26
CA2441386A1 (en) 2002-11-14
ATE298341T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
DE60204767D1 (de) Metallsubstituierte, nicht zentrosymmetrische phthalocyanin-analoga, deren herstellung und verwendung zur photodynamischen therapie, und als in-vivo-diagnostikum
Bonnett Chemical aspects of photodynamic therapy
Spikes et al. Photodynamic therapy of tumours and other diseases using porphyrins
DE60211918T2 (de) Sulfonierte chlorine als photosensitizer
Chan et al. Cell uptake, distribution and response to aluminium chloro sulphonated phthalocyanine, a potential anti-tumour photosensitizer
Kessel Photodynamic therapy: from the beginning
Vahabi et al. The effect of antimicrobial photodynamic therapy with radachlorin and toluidine blue on streptococcus mutans: an in vitro study
BR9712599A (pt) Processos para o tratamento de um volume particular, de câncer e de um volume de tecido canceroso em tecido e para produzir pelo menos um agente molecular foto-ativo num volume particular de material e aparelhos para o tratamento de um volume particular de tecido de planta ou de animal e para a administração de um tratamento médico foto-dinâmico
ATE555789T1 (de) Pyridazinderivate und deren verwendung als therapeutische mittel
PT1392666E (pt) Derivados do azul de metileno biologicamente activos
ATE259814T1 (de) Substituierte metallphthalocyaninen, ihre herstellung und verwendung
ATE308545T1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE335719T1 (de) Polyamine und ihre therapeutische verwendung
DK1698350T3 (da) Porphyrinbaserede forbindelser til billeddiagnostisk tumorundersögelse og fotodynamisk terapi
Gharesi et al. Effect of photodynamic therapy based on indocyanine green on expression of apoptosis-related genes in human gingival fibroblast cells
ATE530184T1 (de) Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe
Dave et al. Photodynamic therapy: A view through light
Fan et al. ROS conversion promotes the bactericidal efficiency of Eosin Y based photodynamic therapy
CN104650129A (zh) 一种轴向酯键连接哌啶或吗啉衍生物的硅酞菁
Zuk et al. PHARMACOKINETIC AND TISSUE DISTRIBUTION STUDIES OF THE PHOTOSENSITIZER bis (DI‐ISOBUTYLOCTADECYLSILOXY) SILICON 2, 3‐NAPHTHALOCYANINE (isoBOSINC) IN NORMAL AND TUMOR‐BEARING RATS
ITPD20100271A1 (it) Uso di derivati della pentafirina come antimicrobici e disinfettanti
Spinei et al. The antimicrobial activity of photodynamic therapy against Streptococci species in dental biofilm using different photosensitizers: An in vitro study
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
Songca et al. Photodynamic therapy: A new light for the developing world
Witt et al. Tributyrin plus all‐trans‐retinoic acid efficiently induces fetal hemoglobin expression in human erythroleukemia cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition